食管癌的临床病理特征与预后影响因素分析

Clinicopathological characteristics and prognostic factors analysis of patients with esopha-geal cancer

  • 摘要:
    目的 探讨食管癌的临床病理特征与预后影响因素。
    方法 采用回顾性病例对照研究方法。收集2017年1月1日至2020年12月31日河北医科大学第四医院收治的447例食管癌患者的临床病理资料;男312例,女135例;年龄为60(37~82)岁。观察指标:(1)临床病理特征。(2)治疗情况。(3)随访情况。(4)食管癌预后影响因素分析。采用电话或门诊方式进行随访,了解患者生存情况。随访时间截至2021年12月。总生存时间定义为从手术日到死亡或最后1次随访时间。对随访时间>2年的患者进行生存和预后分析。正态分布的计量资料以x±s表示,偏态分布的计量资料以M(范围)表示。计数资料以绝对数表示。采用Kaplan⁃Meier法绘制生存曲线并计算生存率,采用Log⁃Rank检验进行生存分析。单因素分析采用Log⁃Rank检验,多因素分析采用COX风险回归模型。
    结果 (1)临床病理特征。447例患者中,男性占69.80%(312/447),女性占30.20%(135/447);发病年龄为30~39岁、40~49岁、50~59岁、60~69岁、70~79岁、80~89岁分别为3、18、101、229、93、3例;病理学类型为鳞癌、小细胞癌、腺鳞癌、肉瘤样癌、腺癌、神经内分泌癌、未分化癌、腺样囊性癌分别为424、11、4、3、2、1、1、1例;肿瘤位置为胸颈段、胸上段、胸中段、胸下段分别为2、49、273、123例;病理学T(pT)分期为pT0期、pT1a期、pT1b期、pT2期、pT3期、pT4a期、pT4b期分别为6、24、74、59、192、80、12例;病理学N(pN)分期中日本食道学会(JES)分期为pN0期、pN1期、pN2期、pN3期、pN4期分别为207、63、142、28、7例,国际抗癌联盟(UICC)分期为pN0期、pN1期、pN2期、pN3期分别为207、128、76、36例;TNM分期中JES分期为0期、Ⅰ期、Ⅱ期、Ⅲ期、Ⅳa期分别为25、53、127、174、68例,UICC分期为0期、Ⅰa期、Ⅰb期、Ⅱa期、Ⅱb期、Ⅲa期、Ⅲb期、Ⅲc期分别为16、9、53、35、108、96、45、85例。(2)治疗情况。447例患者中,63例行新辅助治疗(12例联合免疫治疗),384例未行新辅助治疗;手术入路为经右胸入路、经左胸入路、经颈腹入路、经左侧胸腹联合入路分别为347、97、2、1例;手术平台为全腔镜食管癌切除术、Hybrid手术、开放式手术分别为316、5、126例;消化道重建途径为后纵隔途径、胸内途径分别为350、97例;手术切缘情况为R0切除、R1切除、R2切除分别为323、116、8例。447例患者中,住院期间死亡6例。(3)随访情况。447例患者均获得术后随访,随访时间为25(2~48)个月,其中随访时间>2年233例,中位生存时间未达到,术后2年总生存率为76.8%。(4)食管癌预后影响因素分析。单因素分析结果显示:性别、新辅助治疗、手术切缘、pT分期、pN分期(JES)、pN分期(UICC)、TNM分期(JES)、TNM分期(UICC)是影响233例食管癌患者预后的相关因素(χ2=6.62,17.81,32.95,37.93,27.06,35.56,45.24,37.84,P<0.05)。多因素分析结果显示:性别、手术切缘、TNM分期(JES)是233例食管癌患者预后的独立影响因素(风险比=0.48,1.94,1.46,95%可信区间为0.25~0.91,1.07~3.52,1.16~1.84,P<0.05)。
    结论 食管癌患者中男性发病占比较高,发病年龄60~69岁比例最高,病理学类型以鳞癌为主,肿瘤分期较晚;新辅助治疗比例低,手术治疗R0切除率高;性别、手术切缘、TNM分期(JES)是食管癌患者预后的独立影响因素。

     

    Abstract:
    Objective To investigate the clinicopathological characteristics and prognostic factors of patients with esophageal cancer.
    Methods The retrospective case-control study was conducted. The clinicopathological data of 447 patients with esophageal cancer who were admitted to the Fourth Hospital of Hebei Medical University from January 1, 2017 to December 31, 2020 were collected. There were 312 males and 135 females, aged 60(range, 37‒82)years. Observation indica-tors: (1) clinicopathological characteristics; (2) treatment; (3) follow-up; (4) analysis of prognostic factors for esophageal cancer. Follow-up using telephone interview or outpatient examination was conducted to detect survival of patients up to December 2021. The total survival time was from the surgery date to death or the last follow-up. Patients with duration of follow-up more than 2 years were included for survival and prognostic analysis. Measurement data with normal distribution were represented as Mean±SD, and measurement data with skewed distribution were represented as M(range). Count data were represented as absolute numbers. Kaplan-Meier method was used to draw survival curves and calculate survival rates. Log-Rank test was used for survival analysis. Univariate analysis was conducted using the Log-rank test. Multivariate analysis was conducted using the COX hazard regression model.
    Results (1) Clinicopathological characteristics. Of the 447 patients, 69.80%(312/447) were males and 30.20%(135/447) were females, and there were 3, 18, 101, 229, 93, 3 cases aged 30‒39 years, 40‒49 years, 50‒59 years, 60‒69 years, 70‒79 years, 80‒89 years, respectively. About the pathological type, there were 424 cases with squamous carcinoma, 11 cases with small cell carcinoma, 4 cases with adenosquamous carcinoma, 3 cases with sarco-matoid carcinoma, 2 cases with adenocarcinoma, 1 case with neuroendocrine carcinoma, 1 case with undifferentiated carcinoma, and 1 case with adenoid cystic carcinoma. There were 2 cases with tumor located at cervicothoracic segment, 49 cases with tumor located at upper thoracic segment, 273 cases with tumor located at mid-thoracic segment, and 123 cases with tumor located at lower thoracic segment. There were 6, 24, 74, 59, 192, 80, 12 cases in stage pT0, pT1a, pT1b, pT2, pT3, pT4a, pT4b of pathological T staging, respectively. There were 207, 63, 142, 28, 7 cases in stage pN0, pN1, pN2, pN3, pN4 of pathological N staging by Japan Esophagus Society (JES), respectively. There were 207, 128, 76, 36 cases in stage pN0, pN1, pN2, pN3 of pathological N staging by Union for International Cancer Control (UICC), respectively. About TNM staging, there were 25, 53, 127, 174, 68 cases in stage 0, Ⅰ, Ⅱ, Ⅲ, Ⅳa of JES staging, and 16, 9, 53, 35, 108, 96, 45, 85 cases in stage 0, Ⅰa, Ⅰb,Ⅱa, Ⅱb, Ⅲa, Ⅲb, Ⅲc of UICC staging, respectively. (2) Treatment. Of the 447 patients, 63 cases underwent neoadjuvant therapy(12 cases combined with immunotherapy), 384 cases underwent no neoadjuvant therapy. There were 347, 97, 2, 1 cases with surgical approach as right thoracic approach, left thoracotomy approach, cervical abdominal approach, left thoracoabdominal approach, respectively. There were 316, 5, 126 cases with surgical platform as totally endoscopic esophagec-tomy, Hybrid surgery, open surgery, respectively. There were 350 and 97 cases with digestive recons-truction as posterior mediastinal approach and intrathoracic approach, respectively. Surgical margin as R0, R1, R2 resection was detected in 323, 116, 8 cases, respectively. Six of 447 patients died during the hospital stay. (3) Follow-up. All the 447 patients were followed up for 25(range, 2‒48)months, including 233 cases with the follow-up more than 2 years. The median survival time of 233 patients was unreached, and the postoperative 2-year survival rate was 76.8%. (4) Analysis of prognostic factors for esophageal cancer. Results of univariate analysis showed that gender, neoadjuvant therapy, surgical margin, pT staging, pN staging by JES, pN staging by UICC, TNM staging by JES, TNM staging by UICC were related factors influencing prognosis of 233 patients with esophageal cancer (χ2=6.62, 17.81, 32.95, 37.93, 27.06, 35.56, 45.24, 37.84, P<0.05). Results of multivariate analysis showed that gender, surgical margin, TNM staging by JES were independent factors influencing prognosis of 233 patients with esophageal cancer (hazard ratio=0.48, 1.94, 1.46, 95% confidence intervals as 0.25‒0.91, 1.07‒3.52, 1.16‒1.84, P<0.05).
    Conclusions The incidence of esophageal cancer is relatively high in males, with the onset age mainly distribute in 60‒69 years and the mainly pathological type as squamous carcinoma. Patients with esophageal cancer have advanced tumor staging, low proportion of neoadjuvant therapy, high R0 resection rate of surgical treatment. Gender, surgical margin, TNM staging by JES are independent factors influencing prognosis of patients with esophageal cancer.

     

/

返回文章
返回